Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

News SummaryMost relevantAll newsSector newsTweets

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 07:01pm CET
   By Peter Loftus 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
12/15 BRISTOL MYERS SQUIBB : Myers teams up with Opdivo maker Ono Pharmaceutical on ne..
12/15 SEATTLE GENETICS : and Bristol-Myers Squibb Highlight Interim Results from Phase..
12/15 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Accepts Bristol-M..
12/14 BRISTOL MYERS SQUIBB : Named One of America’s Most JUST Companies in 2017 ..
12/14 BRISTOL MYERS SQUIBB : Study Results from Bristol-Myers Squibb in the Area of Au..
12/14 BRISTOL MYERS SQUIBB : Research Data from Bristol-Myers Squibb Co. Update Unders..
12/14 BRISTOL MYERS SQUIBB : Study Results from Bristol-Myers Squibb Broaden Understan..
12/14 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Report Details of N..
12/14 BRISTOL MYERS SQUIBB : Granted Exclusive License by Ono Pharmaceutical for Multi..
12/13 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Accepts Bristol-M..
More news
News from SeekingAlpha
08:05a 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 17, 2017
12/15 European advisory group backs label expansion for Bristol-Myers' Yervoy
12/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 15, 2017
12/15 YOUR DAILY PHARMA SCOOP : Conatus Looks Undervalued, Teva Announces Restructurin..
12/14 Bristol-Myers in-licenses Ono's cancer candidate ONO-4578
Financials ($)
Sales 2017 20 634 M
EBIT 2017 5 598 M
Net income 2017 4 351 M
Debt 2017 252 M
Yield 2017 2,53%
P/E ratio 2017 24,17
P/E ratio 2018 21,10
EV / Sales 2017 4,96x
EV / Sales 2018 4,74x
Capitalization 102 B
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 63,8 $
Spread / Average Target 2,3%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386